Plant Name: Magnolia pterocarpa
Taxonomic Information:
Plant ID: NPO9505
Plant Latin Name: Magnolia pterocarpa
Taxonomy Genus: Magnolia
Taxonomy Family: Magnoliaceae
Plant External Links:
NCBI TaxonomyDB:
86734
Plant-of-the-World-Online:
554815-1
Used in Medicines:
Unknown.
Geographical Distribution:
Nepal; India; Bangladesh; Myanmar
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2A; ADRA2C; | |
| NMUR2; | |
| ALPI; AKR1B1; POLB; | |
| GAA; ACHE; | |
| MAPK1; | |
| CA2; CA1; CA7; CA4; CA12; CA9; CA14; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.135E-13 | 9.299E-10 | CA1, CA12, CA2, CA4, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.929E-06 | 3.500E-03 | CA2, CA7 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.870E-06 | 3.500E-03 | ALPI, CA1, CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.929E-06 | 3.500E-03 | ADRA2A, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 3.856E-06 | 4.939E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 3.856E-06 | 4.939E-03 | ADRA2A, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 5.159E-06 | 6.241E-03 | ADRA2A, AKR1B1, CA12, CA2, CA7, MAPK1, NMUR2 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 9.631E-06 | 8.388E-03 | CA1, CA2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.690E-19 | 8.035E-15 | CA1, CA12, CA14, CA2, CA4, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.172E-15 | 1.576E-11 | CA1, CA12, CA14, CA2, CA4, CA7, CA9 |
| CC | GO:0016020; membrane | GO:0005886; plasma membrane | 1.379E-05 | 1.076E-02 | ACHE, ADRA2A, ADRA2C, ALPI, CA12, CA14, CA2, CA4, CA9, GAA, MAPK1, NMUR2 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.384E-05 | 1.076E-02 | ADRA2A, CA2, CA4, CA9 |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.796E-05 | 1.304E-02 | ADRA2A, ADRA2C |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 8.735E-19 | 9.084E-17 | CA12, CA1, CA2, CA4, CA7, CA9, CA14 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 2.956E-04 | 7.686E-03 | MAPK1, ADRA2C, ADRA2A |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.503E-04 | 7.686E-03 | CA2, CA4 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 2.576E-04 | 7.686E-03 | GAA, AKR1B1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.288E-03 | 2.678E-02 | NMUR2, ADRA2C, ADRA2A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 3.482E-03 | 6.035E-02 | ACHE, MAPK1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 7.635E-02 | 1.287E-01 | MAPK1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04916 | Melanogenesis | 7.710E-02 | 1.287E-01 | MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 7.784E-02 | 1.287E-01 | MAPK1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 7.784E-02 | 1.287E-01 | MAPK1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
